Abstract
Background HIV pre-exposure prophylaxis (PrEP) has been recommended and partly subsidized in Québec since 2013. We aimed to evaluate the population-level impact of PrEP on HIV transmission among men who have sex with men (MSM) in Montréal over 2013-2021.
Methods We used an agent-based mathematical model of sexual HIV transmission to estimate the fraction of HIV acquisitions averted by PrEP compared to a counterfactual scenario without PrEP. The model was calibrated to local MSM survey and cohort data and accounted for COVID-19 pandemic impacts on sexual activity, prevention, and care. To assess potential optimization strategies, we modelled hypothetical scenarios prioritizing PrEP to MSM with high sexual activity or aged ≤45 years, increasing coverage to levels achieved in Vancouver (where PrEP is free-of-charge), and improving retention.
Results Over 2013-2021, the estimated annual HIV incidence decreased from 0.4 (90% credible interval [CrI]: 0.3-0.6) to 0.2 (90%CrI: 0.1-0.2) per 100 person-years. PrEP coverage in HIV-negative MSM remained low until 2015 (<1%). Afterward, coverage increased to a maximum of 10% (15% of those eligible for PrEP) and the cumulative fraction of HIV acquisitions averted over 2015-2021 was 20% (90%CrI: 11%-30%). The hypothetical scenarios modelled showed that PrEP could have averted up to 63% (90%CrI: 54%-70%) of acquisitions if coverage reached 10% in 2015 and 30% in 2019, like in Vancouver.
Interpretation PrEP reduced population-level HIV transmission among Montréal MSM. However, our study suggests missed prevention opportunities and provides support for public policies that provide PrEP free-of-cost to MSM at high risk of HIV acquisition.
Competing Interest Statement
JC has investigator-sponsored research grants from Gilead Sciences Canada and ViiV Healthcare. He has also received financial support for conference travel and advisory work for Gilead Sciences Canada, Merck Canada and ViiV Healthcare. MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., contractual arrangements from the World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Institut national de santé publique du Québec (INSPQ), and the Institut d'excellence en santé et services sociaux (INESSS), all outside of the submitted work. CT has investigator-sponsored research grants from Merck and Gilead Sciences Canada, and has received financial support for advisory work and conferences from Gilead Sciences Canada, Merck, Medicago, Astra-Zeneca, Pfizer, Sanofi, and GSK. J-GB has received honoraria for consulting for ViiV, Healthcare, Merck, and Gilead Sciences Canada and for participation as a speaker at conferences supported by Merck and Gilead Sciences unrelated to this work. RéZO (AD-B) has received sponsorships from Gilead Sciences Canada.
Funding Statement
CMD is supported by a doctoral award from the Fonds de recherche du Québec-Santé (FRQS). Grants from the Canadian Foundation for AIDS Research and the Canadian Institutes of Health Research (CIHR) to MM-G. MM-G's research program is funded by the Tier 2 Canada Research Chair in Population Health Modelling. SM is supported the Tier 2 Canada Research Chair in Mathematical Modelling and Program Science and the Ontario HIV Treatment Network. CT is the Pfizer/Université de Montréal Chair in HIV Translational Research. MCB acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. For the purpose of open access, MCB has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising. DG is supported by the Tier 2 Canada Research Chair in Sexual and Gender Minority Health Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the McGill University Research Ethics Board gave ethical approval for this work. The IRB of the Research Institute of the McGill University Health Centre gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial sponsors: CMD is supported by a doctoral award from the Fonds de recherche du Québec – Santé (FRQS). Grants from the Canadian Foundation for AIDS Research and the Canadian Institutes of Health Research (CIHR) to MM-G. MM-G’s research program is funded by the Tier 2 Canada Research Chair in Population Health Modelling. SM is supported the Tier 2 Canada Research Chair in Mathematical Modelling and Program Science and the Ontario HIV Treatment Network. CT is the Pfizer/Université de Montréal Chair in HIV Translational Research.
MCB acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. For the purpose of open access, MCB has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising. DG is supported by the Tier 2 Canada Research Chair in Sexual and Gender Minority Health Research.
Conflict of interest statement: JC has investigator-sponsored research grants from Gilead Sciences Canada and ViiV Healthcare. He has also received financial support for conference travel and advisory work for Gilead Sciences Canada, Merck Canada and ViiV Healthcare. MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc., contractual arrangements from the World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Institut national de santé publique du Québec (INSPQ), and the Institut d’excellence en santé et services sociaux (INESSS), all outside of the submitted work. CT has investigator-sponsored research grants from Merck and Gilead Sciences Canada, and has received financial support for advisory work and conferences from Gilead Sciences Canada, Merck, Medicago, Astra-Zeneca, Pfizer, Sanofi, and GSK. J-GB has received honoraria for consulting for ViiV, Healthcare, Merck, and Gilead Sciences Canada and for participation as a speaker at conferences supported by Merck and Gilead Sciences unrelated to this work.
Disclosures: RÉZO (AD-B) has received sponsorships from Gilead Sciences Canada.
Data Availability
The data that support the findings of this study are available from Engage‐ Montréal but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Engage‐Montréal.
